Polyrizon Signs Agreements for Nasarix Human Study

MT Newswires Live06-15

Polyrizon (PLRZ) has entered into agreements with a European university medical center and a clinical research organization to conduct a human study for its Nasarix allergy blocker, the company said Monday.

The study will evaluate the nasal residence time of Nasarix, measuring how long the formulation remains in the nasal cavity after administration, Polyrizon said.

The company said it has engaged the clinical research organization to manage study operations and regulatory submissions.

Nasarix is an investigational intranasal hydrogel formulation designed to create a physical barrier in the nasal cavity to reduce allergen exposure, Polyrizon said.

Shares of Polyrizon were 6.5% higher in Monday premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment